We are searching for the next generation of treatments to help people achieve healthy skin. Drug discovery is an exciting but challenging field where at least nine out of ten early ideas don’t make it to the late stages of development.
The odds of success through LEO Pharma Open Innovation are no different, so most of the compounds we screen are not considered for future pursuit by LEO Pharma. That means you should be realistic about what will come from the Open Innovation partnership: you’ll get data produced by some of LEO Pharma’s best scientists, using unique proprietary assays.
Since you own these data, you can publish them; use them to support grant applications; or build them into the ongoing rationale for future exploration of your compound’s bio-medical potential. You’ll also be much more aware of what we’re looking for and how we operate, so your participation puts you in a stronger position to bring us something else valuable in the future, perhaps a compound or target that we’d never even thought about before. Without the need to disclose the details of your compound, you have (aside from a small volume of your compound) nothing to lose, but perhaps a great deal to gain.
All the data generated by testing your compounds in LEO Pharma's disease-relevant in vitro assays will be reported to you in full. LEO Pharma will only use the generated data to evaluate if a continued collaboration is of interest. You may use the data generated in any way, including for scientific publication. If so, we ask that you notify us about such publication.
If the results indicate an interesting possibility we will suggest a follow-up profiling, which could include studies to address:
- Additional in vitro assays,
- profiling Cytotoxicity Drug Metabolism and Pharmacokinetic evaluation
- Compound physical and chemical properties
- Testing for in vivo effect
The details of the follow-up profiling will be handled on a case-by-case basis.
Please note that lack of biological effect in the Open Innovation assays doesn’t necessarily mean that the compound is concluded to be without value. It might simply be that it doesn’t fit in the current disease and technology platform, or that the compound targets a pathway that is not present in the in vitro assay.
Case-by-case evaluation and discussion under CDA
Should data look promising, we will return with a suggestion to sign a Confidentiality Disclosure Agreement (CDA) in order to continue with a more detailed follow-up discussion to assess how working together could be of benefit to you, to us and most importantly to patients.